Anlon Healthcare Limited IPO

1. We are subject to stringent quality specifications and regular customer audits. Non-compliance may result in order cancellations, warranty claims, or reputational damage. In the past, our manufacturing facility was non-operational for a period of four (4) months to address certain directions and recommendations issued by the Brazilian Health Regulatory Agency, which temporarily halted our manufacturing operations.

2. Any failure to maintain product quality or comply with evolving quality standards may lead to customer dissatisfaction, loss of business, and legal liability.

3. We have a limited operating history in manufacturing.

4. In the past, our Manufacturing Facility remained non-operational for a period of four (4) months, resulting in a halt in our manufacturing capabilities. Any future event that causes a temporary or prolonged shutdown of our Manufacturing Facility could significantly impact our production capacity, disrupt our supply chain, and adversely affect our business operations.

5. Our Company is yet to place orders for the equipment, plant and machinery for the expansion of the Manufacturing Facility. Any delay in placing orders or procurement of such equipment, plant and machinery may delay the schedule of implementation and possibly increase the cost of commencing operations.

6. Our products are exposed to risks of contamination, adulteration, and tampering during manufacturing, storage, or transit, which may adversely impact product quality, lead to regulatory non-compliance, and result in reputational and financial loss.

7. We are exposed to risks of product recalls and liability claims, which may involve significant costs, reputational harm, and regulatory consequences.

8. Our revenue from operations is dependent upon a limited number of customers and the loss of any of these customers or loss of revenue from any of these customers could have a material adverse effect on our business, financial condition, results of operations and cash flows.

9. We derive majority of our revenue from the sale of our products to various segments of pharmaceutical Industry and any reduction in demand for our customer products, or if such products become obsolete due to a breakthrough in the development of alternate drugs, could have an adverse effect on our business.

10. Comparison of our valuation multiples with peer companies may highlight potential investment risks.